{'52WeekChange': 0.70303035,
 'SandP52WeekChange': None,
 'address1': '400 Crossing Boulevard',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.43,
 'askSize': 900,
 'averageDailyVolume10Day': 694375,
 'averageVolume': 540750,
 'averageVolume10days': 694375,
 'beta': None,
 'beta3Year': None,
 'bid': 5.42,
 'bidSize': 1800,
 'bookValue': 2.44,
 'category': None,
 'circulatingSupply': None,
 'city': 'Bridgewater',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.68,
 'dayLow': 5.41,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 10.175,
 'enterpriseToRevenue': 2.014,
 'enterpriseValue': 466425984,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '908 809 1301',
 'fiftyDayAverage': 6.403714,
 'fiftyTwoWeekHigh': 9.67,
 'fiftyTwoWeekLow': 2.7,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14731745,
 'forwardEps': -0.67,
 'forwardPE': -8.089552,
 'fromCurrency': None,
 'fullTimeEmployees': 379,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.44037998,
 'heldPercentInstitutions': 0.44102,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/osmotica.com',
 'longBusinessSummary': 'Osmotica Pharmaceuticals plc, an integrated '
                        'biopharmaceutical company, focuses on the development '
                        'and commercialization of pharmaceutical products in '
                        'the United States, Argentina, and Hungary. The '
                        "company's promoted products include M-72, a "
                        'methylphenidate hydrochloride extended-release tablet '
                        'to treat attention deficit hyperactivity disorder '
                        '(ADHD); Osmolex ER, an amantadine extended-release '
                        "tablet for the treatment of Parkinson's and "
                        'drug-induced extrapyramidal reactions in adults; '
                        'Lorzone, a chlorzoxazone scored tablet for muscle '
                        'spasms; ConZip, a tramadol hydrochloride '
                        'extended-release capsule to treat pain; and '
                        'Arbaclofen tablets which is in phase III clinical '
                        'trial for the treatment of multiple sclerosis '
                        "spasticity. It also provides women's health products, "
                        'including Divigel for menopause, as well as OB '
                        'Complete, a dietary supplement for prenatal, '
                        'pregnancy, and postnatal periods; and RVL-1201, an '
                        'oxymetazoline hydrochloride ophthalmic solution for '
                        'the treatment of Blepharoptosis. In addition, the '
                        "company's non-promoted products comprise "
                        'methylphenidate ER tablets for ADHD; venlafaxine ER '
                        'tablets to treat major depressive disorder and social '
                        'anxiety disorder; hydromorphone ER for treating pain; '
                        'nifedipine ER for hypertension; sodium '
                        'benzoate/sodium phenylacetate for the treatment of '
                        'hyperammonemia; oxybutynin ER for overactive bladder; '
                        'and prescription prenatal vitamins for treating '
                        'nutritional requirements during pregnancy, as well as '
                        'Osmodex and other abbreviated new drug applications. '
                        'Osmotica Pharmaceuticals plc is headquartered in '
                        'Bridgewater, New Jersey.',
 'longName': 'Osmotica Pharmaceuticals plc',
 'market': 'us_market',
 'marketCap': 318483008,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_579085729',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -267296992,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '908 809 1300',
 'previousClose': 5.62,
 'priceHint': 2,
 'priceToBook': 2.2213116,
 'priceToSalesTrailing12Months': 1.3754157,
 'profitMargins': -1.1543599,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.68,
 'regularMarketDayLow': 5.41,
 'regularMarketOpen': 5.6,
 'regularMarketPreviousClose': 5.62,
 'regularMarketPrice': 5.6,
 'regularMarketVolume': 375774,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 58760700,
 'sharesPercentSharesOut': 0.0147,
 'sharesShort': 868198,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 590816,
 'shortName': 'Osmotica Pharmaceuticals plc',
 'shortPercentOfFloat': 0.0734,
 'shortRatio': 2.07,
 'startDate': None,
 'state': 'NJ',
 'strikePrice': None,
 'symbol': 'OSMT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.968,
 'twoHundredDayAverage': 5.242446,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '6367789e-531c-3f48-b1e9-0fbef116ae71',
 'volume': 375774,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.osmotica.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '08807'}